CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon

Bulletin Express

07/22

China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.

The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.

The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1111875986"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111875986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111875986?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111875986","market":"us","top_or_hot":-1,"title":"CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.</p>\n<p>The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.</p>\n<p>The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n<p>The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-22 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.</p>\n<p>The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.</p>\n<p>The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n<p>The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1111875986","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111875986","pubTimestamp":1784715639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药以1.53%票面完成首批10亿元中期票据发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.\nThe offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.\nThe transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.\nThe board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}